GHR and neoplasm: Single agent growth-inhibitory effects have been reported in breast, colon, and meningioma tumor xenografts, which suggests that GHR antagonism as a monotherapy may have efficacy in some tumor types.71–74 However, it is clear from these studies that not all tumor types tested were responsive, and currently the field is lacking diagnostic biomarkers capable of predicting response.